Print

Isotechnika Pharma Inc. (ISA.TO) Announces Agreement With National Institutes of Health (NIH) to Evaluate NICAM Portfolio as Anti-Viral Agents  
4/11/2012 9:33:21 AM

EDMONTON, Alberta, April 11, 2012 (GLOBE NEWSWIRE) -- Isotechnika Pharma Inc. (TSX:ISA) ("Isotechnika" or the "Company") is pleased to announce the signing of a three year Non-Clinical Evaluation Agreement with the National Institute of Allergy and Infectious Diseases ("NIAID"), part of the U.S. National Institutes of Health ("NIH"). Pursuant to the agreement, NIAID-funded contractors will evaluate the Company's portfolio of non-immunosuppressive cyclosporine analogue molecules ("NICAMs") as anti-viral agents.